论文部分内容阅读
目的探讨支气管扩张伴气流受限患者应用沙美特罗替卡松气雾剂治疗的临床效果。方法选取2012年9月至2015年1月本溪市中心医院收治的60例支气管扩张伴气流受限患者作为研究对象,按随机数字表法将其分为对照组和试验组,各30例。对照组患者实施常规对症治疗,试验组患者在对照组基础上吸入沙美特罗替卡松气雾剂,比较两组患者治疗前后肺功能情况。结果治疗后,试验组患者的BODE指数评分、FENO均明显低于对照组,FEV1/FVC明显高于对照组,差异均有统计学意义(均P<0.05)。结论对支气管扩张伴气流受限患者基于常规治疗加用沙美特罗替卡松气雾剂,所获疗效较理想,可明显改善患者的肺功能。
Objective To investigate the clinical effect of salmeterol and fluticasone aerosol in patients with limited bronchiectasis and airflow limitation. Methods Sixty patients with bronchiectasis with airflow limitation from September 2012 to January 2015 in Benxi Central Hospital were enrolled in this study. They were divided into control group and trial group according to random number table. Patients in the control group were treated with conventional symptomatic treatment. Patients in the test group were given inhaled salmeterol and fluticasone propionate aerosol on the basis of the control group, and the pulmonary function of the two groups was compared before and after treatment. Results After treatment, BODE index and FENO in test group were significantly lower than those in control group, FEV1 / FVC was significantly higher than that in control group (all P <0.05). Conclusions The patients with limited bronchiectasis and airflow limitation were treated with salmeterol and fluticasone propionate aerosols on the basis of routine therapy and the results were satisfactory and the lung function of patients could be obviously improved.